Inventor · disambiguated record
Paul E. Fleming
Also filed as: FLEMING PAUL · FLEMING PAUL A · FLEMING PAUL E
32 granted patents·11 pending applications·185 citations·filing 2002–2024
96Inventor score
Files withMILLENNIUM PHARM INC25AKEBIA THERAPEUTICS INC6BLUEPRINT MEDICINES CORP6FLEMING PAUL E4MILLENNIUM PHARMECEUTICALS INC1
Top patents by PatentIndex Score
43 records- 0196US10227329B2Compounds useful for treating disorders related to RETBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 12, 2019·19 cites·21 claims
- 0294US10202365B22-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitorsBLUEPRINT MEDICINES CORP·Filed 2016·Granted Feb 12, 2019·20 cites·15 claims
- 0393US10233186B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2017·Granted Mar 19, 2019·16 cites·56 claims
- 0492US10774070B22-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitorsBLUEPRINT MEDICINES CORP·Filed 2018·Granted Sep 15, 2020·6 cites·14 claims
- 0592US7282502B2CCR9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2006·Granted Oct 16, 2007·24 cites·21 claims
- 0691US7732444B22-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseasesMILLENNIUM PHARM INC·Filed 2005·Granted Jun 8, 2010·25 cites·19 claims
- 0789US7238717B2CCR9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2003·Granted Jul 3, 2007·23 cites·6 claims
- 0887US9290500B2Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzymeMILLENNIUM PHARM INC·Filed 2013·Granted Mar 22, 2016·10 cites·41 claims
- 0987US8030517B2CCR9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2009·Granted Oct 4, 2011·6 cites·14 claims
- 1086US7951801B2Beta-carbolines useful for treating inflammatory diseaseMILLENNIUM PHARM INC·Filed 2005·Granted May 31, 2011·11 cites·6 claims
- 1185US7999109B2CCR9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2009·Granted Aug 16, 2011·4 cites·24 claims
- 1283US11634422B2Inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2020·Granted Apr 25, 2023·1 cites·30 claims
- 1383US7659272B2CCR9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2007·Granted Feb 9, 2010·4 cites·25 claims
- 1482US9751854B2Heteroaryls and uses thereofMILLENNIUM PHARM INC·Filed 2016·Granted Sep 5, 2017·3 cites·8 claims
- 1582US7820717B2CCR9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2008·Granted Oct 26, 2010·3 cites·5 claims
- 1681US9802960B2Heteroaryls and uses thereofMILLENNIUM PHARM INC·Filed 2015·Granted Oct 31, 2017·4 cites·29 claims
- 1773US10202373B2Heteroaryls and uses thereofMILLENNIUM PHARM INC·Filed 2015·Granted Feb 12, 2019·2 cites·15 claims
- 1873US8569543B2CCR9 inhibitors and methods of use thereofFLEMING PAUL E·Filed 2011·Granted Oct 29, 2013·1 cites·7 claims
- 1973US8513218B2Derivatives of 1-amino-2-cyclopropylethylboronic acidFLEMING PAUL E·Filed 2011·Granted Aug 20, 2013·1 cites·22 claims
- 2072US11236086B2Substituted pyrrolopyridines as inhibitors of activin receptor-like kinaseBLUEPRINT MEDICINES CORP·Filed 2018·Granted Feb 1, 2022·1 cites·19 claims
- 2172US9663525B2Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzymeMILLENNIUM PHARM INC·Filed 2016·Granted May 30, 2017·1 cites·12 claims
- 2267US2024336568A1Selective phd1 inhibitor compounds, compositions, and methods of useAKEBIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2367US2024327376A1Picolinamide compounds as selective phd1 inhibitors, compositions, and methods of useAKEBIA THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2466US9035096B2CCR9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2013·Granted May 19, 2015·0 cites·21 claims
- 2566US8664200B2Derivatives of 1-amino-2-cyclobutylethylboronic acidFLEMING PAUL E·Filed 2009·Granted Mar 4, 2014·0 cites·13 claims
- 2664US9023832B2Derivatives of 1-amino-2-cyclopropylethylboronic acidMILLENNIUM PHARM INC·Filed 2014·Granted May 5, 2015·0 cites·21 claims
- 2762US9771381B2Derivatives of 1-amino-2-cyclobutylethylboronic acidMILLENNIUM PHARM INC·Filed 2014·Granted Sep 26, 2017·0 cites·2 claims
- 2861US10202389B2Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzymeMILLENNIUM PHARM INC·Filed 2017·Granted Feb 12, 2019·0 cites·7 claims
- 2961US10035811B2Derivatives of 1-amino-2-cyclobutylethylboronic acidMILLENNIUM PHARM INC·Filed 2017·Granted Jul 31, 2018·0 cites·2 claims
- 3061US9796725B2Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzymeMILLENNIUM PHARM INC·Filed 2017·Granted Oct 24, 2017·0 cites·15 claims
- 3161US8703743B2Derivatives of 1-amino-2-cyclopropylethylboronic acidMILLENNIUM PHARM INC·Filed 2013·Granted Apr 22, 2014·0 cites·100 claims
- 3261US2007066823A1CCR9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2006·Application pending·0 cites
- 3358US2016068479A1Ccr9 inhibitors and methods of use thereofMILLENNIUM PHARMECEUTICALS INC·Filed 2015·Application pending·0 cites
- 3457US2010324093A1Ccr9 inhibitors and methods of use thereofMILLENNIUM PHARM INC·Filed 2010·Application pending·0 cites
- 3556US2010093713A1Beta-carbolines useful for treating inflammatory diseaseMILLENNIUM PHARM INC·Filed 2009·Application pending·0 cites
- 3652US10538533B2Heteroaryls and uses thereofMILLENNIUM PHARM INC·Filed 2017·Granted Jan 21, 2020·0 cites·23 claims
- 3750US2023295110A1Phd inhibitor compounds, compositions, and methods of useAKEBIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3849US7727985B2Beta-carbolines useful for treating inflammatory diseaseMILLENNIUM PHARM INC·Filed 2004·Granted Jun 1, 2010·0 cites·5 claims
- 3949US2023159489A1Phd inhibitor compounds, compositions, and useAKEBIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4048US2023227426A1Phd inhibitor compounds, compositions, and useAKEBIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4147US2023212138A1Phd inhibitor compounds, compositions, and their useAKEBIA THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4243US2003134266A1Methods of screening for compounds that modulate blood vessel formationUNIV SOUTH CAROLINA·Filed 2002·Application pending·0 cites
- 4342US8268822B22-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseasesFLEMING PAUL E·Filed 2010·Granted Sep 18, 2012·0 cites·11 claims
Join the waitlist — get patent alerts
Get an alert when Paul E. Fleming files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →